期刊文献+

卡维地洛治疗缺血性心肌病心力衰竭的临床观察 被引量:4

下载PDF
导出
摘要 目的探讨β受体阻滞剂卡维地洛对缺血性心肌病心力衰竭患者心功能、QT离散度及室性心律失常(VA)的干预作用。方法选择缺血性心脏病心力衰竭132例,随机分为对照组和治疗组(每组66例),对照组给予常规治疗(ACEI/ARb、利尿剂、地高辛);治疗组在对照组治疗的基础上,加用卡维地洛。两组均治疗6个月。治疗前后应用24 h动态心电图观察QTd、QTcd、室性心律失常的发生情况,多普勒超声心动图观察左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)。结果治疗6个月后,治疗组QTd、QTcd及VA发生率均较对照组治疗后显著降低(P<0.05),LVEDD和LVESD与对照组治疗后比较明显缩小(P<0.05),LVEF较对照组治疗后明显提高(P<0.05)。结论缺血性心肌病患者长期应用卡维地洛可显著降低QTd、QTcd及VA发生率,改善心功能,改善预后。
机构地区 解放军
出处 《西南国防医药》 CAS 2010年第3期269-270,共2页 Medical Journal of National Defending Forces in Southwest China
  • 相关文献

参考文献8

  • 1Packer M, Coasts A J, Fowler M B, et al. Effect of carvedilol on survival in severe chronic heart failure[J]. N Engl J Med,2001, 344(22) :1651 - 1658.
  • 2Bristow M R. What type of beta - blocker should be used to treat chronic heart failure [J].Circulation, 2001,10:484 - 486.
  • 3施仲伟.β受体阻滞剂治疗慢性心力衰竭的目标剂量问题[J].中华老年多器官疾病杂志,2004,3(3):226-229. 被引量:7
  • 4Merit - HF Study Group. Effect of metoprolol CR/XL in chronic heart failure : metoprolol CR/XL randomized intervention trial in congestive heart failure ( MERIT - HF) [ J ]. Lancet, 1999,353 : 2001 - 2007.
  • 5Bristow M R. Mechanism of action of beta - blocking agents in heart failure[ J ]. Am J Cardiol, 1997,80:26L - 40L.
  • 6Stoschitzky K, Koshueharova G, Zweiker R, et al. Differing beta - blocking effects of carvedilol and metoprolol [ J ]. Eur J Heart Fail ,2001,3 ( 3 ) :343 - 349.
  • 7Barr C S, Naas A, Freeman M, et al. QT dispersion and sudden unexpected death in chronic heart failure[ J]. Lancet, 1994,343 (8893) :327 - 329.
  • 8Bril A, Tomasi V, Lville M P. Antiarrhythmic effect of carvedilol in rat isolated heart subjected to regional ischaemia and reperfusion[ J]. Pbarmaeol Commun, 1995,5:291 - 300.

二级参考文献17

  • 1[1]CIBIS-Ⅱ Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study Ⅱ (CIBIS Ⅱ): a randomized trial. Lancet, 1999,353: 9-13.
  • 2[2]MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 1999, 353:2001-2007.
  • 3[3]Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001,344:1651-1658.
  • 4[5]Packer M, Cohn JN, Abraham WT, et al. Consensus recommendations for management of chronic heart failure. Am J Cardiol, 1999, 83:1A-38A.
  • 5[6]Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treartment of chronic heart failure. Eur Heart J,2001, 22:1527-1560.
  • 6[7]Bristow MR, Gilbert EM, Abraham WT, et al. Carvediol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation,1996, 94:2807-2816.
  • 7[8]Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure. Analysis of the experience in Metoprolol CR/XL Randomized International Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol, 2002, 40:491-498.
  • 8[9]Simon T, Mary-Krause M, Furck-Brentano C, et al. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgpoup analysis in the cardiac insufficiency bisoprolol study (CIBIS Ⅱ ). Eur Heart J, 2003, 24:552-559.
  • 9[10]Poole-Wilson PA, Cleland JGF, Lenarda AD, et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur J Heart Fail,2002, 4:321-329.
  • 10[11]Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 2003, 362:7-13.

共引文献6

同被引文献33

  • 1罗巍,陈云辉,方长庚,陈俊东,曾小茹,王俊容.β受体阻滞剂应用于COPD并慢性心功能不全的临床观察[J].临床肺科杂志,2006,11(3):324-325. 被引量:10
  • 2李贵才,李艳,孙桂锋.卡维地洛治疗急性心肌梗死并心力衰竭的疗效观察[J].实用心脑肺血管病杂志,2006,14(5):378-379. 被引量:3
  • 3E 特勒帕吉克塞尔,A 穆尼奥萨阿尔韦霄兹,M 波马雷斯马尔科,等.制备书维地洛及其对映异构体的方法..中国:CN101072753[P].2007-11-14.
  • 4金成镇,全龙国,姜炫彬.制备高光学纯卡维地洛的工艺..中国:CN101389605[P].2009-03-18.
  • 5KUMAR ASHOK,SAXENA ASHVINI,BHATTACHARYYA ANINDYA, et al. Process for the preparation of Carvedilot:EP, 1741700[P].2006.
  • 6DOLITZKY BEN-ZION,ARONHIME JUDITH,HILDESHIM JEAM, et al. CarvedilohEP, 129910[P].2001.
  • 7田颖,祝善俊,王江,李振魁,宋熔,聂凌.美托洛尔和卡维地洛对慢性心力衰竭的影响[J].中华老年心脑血管病杂志,2007,9(12):814-816. 被引量:17
  • 8Lysko P G,Lysko K A,Yue TL,et al.Neuroprotective effects of carvedilol.a new antihypertensive agent,in cultured rat cerebellar neurons and in gerbil global brain ischemia[J].Stroke Journal of the American Heart Association,1992,23(11):1630-1635.
  • 9McTavish D,Compoli-Richards D,Sorkin E M.Carvedilol,A review of its pharmacodynamic and pharmacokinetic properties,and therapeutic efficacy[J].Drugs,1993,45(2):232-258.
  • 10Ramanjaneyulu G S, Kumar I V S,Rao KN,et al.Process for the preparation of crystalline carvedilol form-II:WO,2004094378[P].2004-11-04.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部